Investigating a new treatment target for rheumatoid arthritis
INPP5E Signaling and Treatment in Rheumatoid Arthritis
This study is looking at a protein called INPP5E to see how it affects inflammation in rheumatoid arthritis, with the hope that understanding it better could lead to new treatment options for people who aren't getting better with current therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10943165 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of INPP5E, a protein that may influence inflammation and immune responses in rheumatoid arthritis (RA). By analyzing human and mouse synovial tissues, the study aims to uncover how changes in INPP5E expression affect macrophages, which are key players in RA inflammation. The researchers will explore whether targeting INPP5E can lead to new therapeutic strategies for patients who do not respond to current treatments. This approach could potentially improve outcomes for those suffering from this debilitating condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with rheumatoid arthritis, particularly those who have not responded well to conventional treatments.
Not a fit: Patients with rheumatoid arthritis who are already effectively managing their condition with current therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for rheumatoid arthritis patients who currently have limited responses to existing therapies.
How similar studies have performed: While the specific role of INPP5E in rheumatoid arthritis is not extensively studied, similar approaches targeting immune signaling pathways have shown promise in other autoimmune conditions.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Yang, Shuying — University of Pennsylvania
- Study coordinator: Yang, Shuying
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.